Equus Receives Notice of Non-Compliance with New York Stock Exchange Share Price Rule

Core Viewpoint - Equus Total Return, Inc. has been notified by the NYSE of non-compliance with listing standards due to its Common Stock trading below $1.00 for a consecutive 30-day period, but this notice does not affect its current listing or trading status [1][4]. Group 1: Compliance Notification - The NYSE notified Equus on May 15, 2025, regarding the non-compliance with Section 802.01C of the NYSE Listed Company Manual [1]. - The notice is classified as a deficiency notice and does not imply immediate delisting [1][4]. Group 2: Plans for Compliance - The Company plans to inform the NYSE by May 25, 2025, of its intention to remedy the stock price deficiency and return to compliance [2]. - Equus can regain compliance within six months if it achieves a closing share price of at least$1.00 on the last trading day of any calendar month during the cure period [2]. Group 3: Potential Actions for Compliance - The Company is considering various alternatives to address the stock price non-compliance, including a reverse stock split, which will be proposed at the upcoming annual meeting on June 26, 2025 [3]. - If the Company takes action requiring stockholder approval, the price condition will be deemed cured if the stock price exceeds $1.00 and remains above that level for at least 30 trading days [3]. Group 4: Ongoing Operations - Equus's Common Stock will continue to be listed and traded on the NYSE during the compliance period, provided it meets other listing standards [4]. - The notice is not expected to impact the Company's ongoing business operations or its reporting obligations with the U.S. Securities and Exchange Commission [4]. Group 5: Company Overview - Equus Total Return, Inc. operates as a business development company and trades as a closed-end fund on the NYSE under the symbol "EQS" [5].